0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

BCVPP Chemotherapy for Advanced Hodgkin's Disease: Evidence for Greater Duration of Complete Remission, Greater Survival, and Less Toxicity Than with a MOPP Regimen: Results of the Eastern Cooperative Oncology Group Study

RICHARD F. BAKEMEIER, M.D.; JAMES R. ANDERSON, Ph.D.; WILLIAM COSTELLO, Ph.D.; GARY ROSNER, M.S.; JOHN HORTON, M.B., Ch.B.; JOHN H. GLICK, M.D.; JOHN D. HINES, M.D.; COSTAN W. BERARD, M.D.; and VINCENT T. DeVITA Jr., M.D.
[+] Article and Author Information

This study was conducted by the Eastern Cooperative Oncology Group (Paul P. Carbone, M.D., Chairman; CA 21115) and supported by Public Health Service grants from the National Cancer Institute, National Institutes of Health, and the Department of Health and Human Services. Participating institutions include: University of Rochester Cancer Center, Rochester, New York (CA 11083); Sidney Farber Cancer Institute, Boston, Massachusetts (CA 23318); Albany Medical College, Albany, New York (CA 06594); Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (CA 15488); Case Western Reserve University, Cleveland, Ohio (CA 14548); St. Jude's Children's Research Hospital, Memphis, Tennessee; National Cancer Institute, Bethesda, Maryland; Albert Einstein College of Medicine, Bronx, New York (CA 14958); University of Alberta, Edmonton, Alberta, Canada; American Oncologic Hospital, Philadelphia, Pennsylvania (CA 18281); Baystate Medical Center, Springfield, Massachusetts (CA 20182); Brookdale Hospital Center, Brooklyn, New York; Brown University, Providence, Rhode Island (CA 15947); Chicago Medical School, Chicago, Illinois (CA 14144); Hahnemann Medical College, Philadelphia, Pennsylvania (CA 13611); University of Iowa, Iowa City, Iowa; Jackson Memorial Hospital, Miami, Florida; Jefferson Medical College, Philadelphia, Pennsylvania (CA 14215); Johns Hopkins Oncology Center, Baltimore, Maryland (CA 16116); Maimonides Medical Center, Brooklyn, New York; Mayo Clinic, Rochester, Minnesota (CA 13650); University of Minnesota, Minneapolis, Minnesota (CA 20365); New York University Medical Center, New York, New York (CA 16395); Northwestern University Medical Center, Chicago, Illinois (CA 17145); University of Ottawa, Ottawa, Ontario, Canada; Pennsylvania Hospital, Philadelphia, Pennsylvania (CA 13613); University of Pittsburgh, Pittsburgh, Pennsylvania (CA 18653); Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois (CA 10948); University of Pretoria, Pretoria, South Africa (CA 21692); SUNY—Stony Brook, Veterans Administration Hospital, Northport, New York (CA 20161); Tufts University, Walpole, Massachusetts (CA 07190); Medical College of Virginia, Richmond, Virginia (CA 10572).

▸Requests for reprints should be addressed to Richard F. Bakemeier, M.D.; University of Rochester Cancer Center, 601 Elm wood Avenue, Box 704; Rochester, NY 14642.


Rochester and Albany, New York; Boston, Massachusetts; Philadelphia, Pennsylvania; Cleveland, Ohio; Memphis, Tennessee; and Bethesda, Maryland


© 1984 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1984;101(4):447-456. doi:10.7326/0003-4819-101-4-447
Text Size: A A A

Two chemotherapy regimens for treatment of patients with advanced Hodgkin's disease, BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone) and MOPP (mechlorethamine hydrochloride, vincristine, procarbazine, and prednisone), were compared in a randomized prospective study. Two hundred ninety-three patients were evaluable in the induction phase of this study. The complete remission rate with BCVPP was 76% (112/147) and with MOPP, 73% (106/146) (p = 0.51). The duration of complete remissions for previously untreated patients given BCVPP was significantly longer than that for previously untreated patients given MOPP (p = 0.02). Although hematologic toxicities were similar, BCVPP caused less gastrointestinal (p = 0.0001) and neurologic toxicity (p = 0.01) than MOPP. Previously untreated patients achieving complete remission with BCVPP survived significantly longer than those receiving MOPP (p = 0.03). As primary induction chemotherapy for advanced Hodgkin's disease, BCVPP is an effective alternative to MOPP, having equal or greater therapeutic benefit with less toxicity.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)